Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage

References

• Murphy GP, Lawrence W Jr, Lenhard RE American Society Textbook of Clinical Oncology, 2nd Ed. Atlanta, GA: American Cancer Society; 1995.
   Google Scholar
• Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 2007; 7: 147–156
   PubMed Web of Science ®Google Scholar
• Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000; 207: 77–86
   PubMed Web of Science ®Google Scholar
• Goormaghtigh E, Brasseur R, Ruysschaert JM. Adriamycin inactivates cytochrome c oxidase by exclusion of the enzyme from its cardiolipin essential environment. Biochem Biophys Res Commun 1982; 104: 314–320
   PubMed Web of Science ®Google Scholar
• Singal PK, Pierce G. Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol 1986; 250: H419–H425
   PubMed Web of Science ®Google Scholar
• Singal PK, Panagia V. Direct effects of adriamycin on the rat heart sarcolemma. Res Commun Chem Pathol Pharmacol 1984; 43: 67–77
   PubMedGoogle Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727–741
   PubMed Web of Science ®Google Scholar
• Gille L, Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med 1997; 23: 775–782
   PubMed Web of Science ®Google Scholar
• Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000; 60: 1789–1792
   PubMed Web of Science ®Google Scholar
• Li T, Danelisen I, Singal PK. Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. Mol Cell Biochem 2002; 232: 19–26
   PubMed Web of Science ®Google Scholar
• Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197: 165–167
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997; 11: 931–936
   PubMed Web of Science ®Google Scholar
• Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 2007; 7: 147–156
   PubMed Web of Science ®Google Scholar
• Bradamante S, Barenghi L, Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 2004; 22: 169–188
   PubMed Web of Science ®Google Scholar
• Fremont L. Biological effects of resveratrol. Life Sci 2000; 66: 663–673
   PubMed Web of Science ®Google Scholar
• Gusman J, Malonne H, Atassi G. Reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001; 22: 1111–1117
   PubMed Web of Science ®Google Scholar
• Virgili M, Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci Lett 2000; 281: 123–126
   PubMed Web of Science ®Google Scholar
• Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002; 106: 1652–1658
   PubMed Web of Science ®Google Scholar
• Dong Z. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat Res 2003; 523–524: 145–150
   PubMed Web of Science ®Google Scholar
• Cao Z, Li Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol 2004; 489: 39–48
   PubMed Web of Science ®Google Scholar
• Ara C, Kirimlioglu H, Karabulut AB, Coban S, Ay S, Harputluoglu M, Kirimlioglu V, Yilmaz S. Protective effect of resveratrol against oxidative stress in cholestasis. J Surg Res 2005; 127: 112–117
   PubMed Web of Science ®Google Scholar
• Ara C, Karabulut AB, Kirimlioglu H, Coban S, Ugras M, Kirimliglu V, Yilmaz S. Protective effect of resveratrol against renal oxidative stress in cholestasis. Ren Fail 2005; 27: 435–440
   PubMed Web of Science ®Google Scholar
• Hascalik S, Celik O, Turkoz Y, Hascalik M, Cigremis Y, Mizrak B, Yologlu S. Resveratrol, a red wine constituent polyphenol, protects from ischemia-reperfusion damage of the ovaries. Gynecol Obstet Invest 2004; 57: 218–223
   PubMed Web of Science ®Google Scholar
• Saito M, Satoh S, Kojima N, Tada H, Sato M, Suzuki T, Senoo H, Habuchi T. Effects of phenolic compound, resveratrol, on the renal function and costimulatory adhesion molecule CD86 expression in rat kidneys with ischemia/reperfusion injury. Arch Histol Cytol 2005; 68: 41–49
   PubMed Web of Science ®Google Scholar
• Solmaz A, Şener G, Çetinel Ş, Yüksel M, Gedik N, Yeğen BÇ, Yeğen C. Protective and therapeutic effects of resveratrol, a red wine polyphenol, on acetic acid-induced gastric damage. Gastroenterology 2008;134:A239–A240.
   Google Scholar
• Sener G, Tuğtepe H, Yüksel M, Cetinel S, Gedik N, Yeğen BC. Resveratrol improves ischemia/reperfusion-induced oxidative renal injury in rats. Arch Med Res 2006; 37: 822–829
   PubMed Web of Science ®Google Scholar
• Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358–367
   PubMed Web of Science ®Google Scholar
• Ohara Y, Peterson TE, Harrisorn DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 92: 2546–2551
   PubMedGoogle Scholar
• Beuge JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302–311
   PubMedGoogle Scholar
• Beutler E. Glutathione in red blood cell metabolism. A manual of biochemical methods. Grune & Stratton, New York 1975; 112–114
   Google Scholar
• Mylorie AA, Collins H, Umbles C, Kyle J. Erythrocyte superoxide dismutase activity and other parameters of cupper status in rats ingesting lead acetate. Toxicol Appl Pharmacol 1986; 82: 512–520
   PubMed Web of Science ®Google Scholar
• Aebi H.E. Catalase. Methods of enzymatic analysis3rd edition, HU. Bergmeyer, J. Bergmeyer, M. Grabl. Velag Chemie Gmbh, Weinheim. 1993; III: 273–286
   Google Scholar
• Hillegass LM, Griswold DE, Brickson B, Albrightson-Winslow C. Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods 1990; 24: 285–295
   PubMedGoogle Scholar
• Kim YK, Lee SH, Goldinger JM, Hong SK. Effect of ethanol on organic ion transport in rabbit kidney. Toxicol Appl Pharmacol 1986; 86: 411–420
   PubMed Web of Science ®Google Scholar
• Reading HW, Isbir T. The role of cation activated ATPase in transmitter release from the rat iris. Q J Exp Physiol 1980; 65: 105–116
   PubMed Web of Science ®Google Scholar
• Fiske CH, SubbaRow Y. The colorimetric determination of phosphorus. J Biol Chem 1925; 66: 375–400
   Google Scholar
• Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurements with the folin phenol reagent. J Biol Chem 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Lopez De Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed parraffin-embedded sections. J Histochem Cytochem 1985; 33: 737–743
   PubMedGoogle Scholar
• Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865–872
   PubMedGoogle Scholar
• Berlin V, Haseltine WA. Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. J Biol Chem 1981; 256: 4747–4756
   PubMed Web of Science ®Google Scholar
• Deepa PR, Varalakshmi P. Influence of a low-molecular-weight heparin derivative on the nitric oxide levels and apoptotic DNA damage in adriamycin-induced cardiac and renal toxicity. Toxicology 2006; 217: 176–183
   Google Scholar
• Stark G. Functional consequences of oxidative membrane damage. J Membr Biol 2005; 205: 1–16
   PubMed Web of Science ®Google Scholar
• Iqbal M, Dubey K, Anwer T, Ashish A, Pillai KK. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 2008; 60: 382–390
   PubMed Web of Science ®Google Scholar
• El-Shitany NA, El-Haggar S, El-desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol 2008; 46: 2422–2428
   PubMed Web of Science ®Google Scholar
• Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007; 49: 330–352
   PubMed Web of Science ®Google Scholar
• Du Y, Lou H. Catechin and proanthocyanidin B4 from grape seeds prevent doxorubicin-induced toxicity in cardiomyocytes. Eur J Pharmacol 2008; 591: 96–101
   PubMed Web of Science ®Google Scholar
• Bast A, Haenen GR, Bruynzeel AM, Van der Vijgh WJ. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials. Cardiovasc Toxicol 2007; 7: 154–159
   PubMed Web of Science ®Google Scholar
• Li T, Danelisen I, Belló-Klein A, Singal PK. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res 2000; 46: 523–530
   PubMed Web of Science ®Google Scholar
• Yagmurca M, Fadillioglu E, Erdogan H, Ucar M, Sogut S, Irmak MK. Erdosteine prevents doxorubicin-induced cardiotoxicity in rats. Pharmacol Res 2003; 48: 377–382
   PubMed Web of Science ®Google Scholar
• You JS, Huang HF, Chang YL, Lee YS. Sheng-mai-san reduces adriamycin-induced cardiomyopathy in rats. Am J Chin Med 2006; 34: 295–305
   Web of Science ®Google Scholar
• Venditti P, Balestrieri M, De Leo T, Di Meo S. Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res 1998; 38: 695–702
   PubMed Web of Science ®Google Scholar
• Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, Otani H, Bagchi D, Das DK, Maulik N. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007; 43: 720–729
   PubMed Web of Science ®Google Scholar
• Lu M, Cai YJ, Fang JG, Zhou YL, Liu ZL, Wu LM. Efficiency and structure-activity relationship of the antioxidant action of resveratrol and its analogs. Pharmazie 2002; 57: 474–478
   Google Scholar
• Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, Shi X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 2003; 309: 1017–1026
   PubMed Web of Science ®Google Scholar
• Radons J, Heller B, Bürkle A, Hartmann B, Rodriguez ML, Kröncke KD, Burkart V, Kolb H. Nitric oxide toxicity in islet cells involves poly(ADP-ribose) polymerase activation and concomitant NAD+ depletion. Biochem Biophys Res Commun 1994; 30: 1270–1277
   Google Scholar
• Pacher P, Liaudet L, Mabley J, Komjáti K, Szabó C. Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 2002; 40: 1006–1016
   Google Scholar
• Dizdaroglu M. Oxidative damage to DNA in mammalian chromatin. Mutat Res 1992; 275: 331–342
   PubMed Web of Science ®Google Scholar
• Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA 1994; 91: 10771–10778
   PubMed Web of Science ®Google Scholar
• Zhou S, Palmeira CM, Wallace KB. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 2001; 121: 151–157
   PubMed Web of Science ®Google Scholar
• Inchiosa MA, Jr, Smith CM. Effects of ibuprofen on doxorubicin toxicity. Res Commun Chem Pathol Pharmacol 1990; 67: 63–78
   Google Scholar
• Arnhold J, Osipov AN, Spalteholz H, Panasenko OM, Schiller J. Effects of hypochlorous acid on unsaturated phosphatidylcholines. Free Radic Biol Med 2001; 31: 1111–1119
   PubMed Web of Science ®Google Scholar
• Kettle AJ, Winterbourn CC. Myeloperoxidase: a key regulator of neutrophil oxidant production. Redox Rep 1997; 3: 3–15
   PubMed Web of Science ®Google Scholar
• Yagmurca M, Fadillioglu E, Erdogan H, Ucar M, Sogut S, Irmak MK. Erdosteine prevents doxorubicin-induced cardiotoxicity in rats. Pharmacol Res 2003; 48: 377–382
   PubMed Web of Science ®Google Scholar
• Hamza A, Amin A, Daoud S. The protective effect of a purified extract of Withania somnifera against doxorubicin-induced cardiac toxicity in rats. Cell Biol Toxicol 2008; 24: 63–73
   PubMed Web of Science ®Google Scholar
• Szewczuk LM, Penning TM. Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. J Nat Prod 2004; 67: 1777–1782
   PubMed Web of Science ®Google Scholar
• Nagi MN, Mansour MA. Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res 2000; 41: 283–289
   PubMed Web of Science ®Google Scholar
• Iliskovic N, Singal PK. Lipid lowering: an important factor in preventing adriamycin induced heart failure. Am J Pathol 1997; 150: 727–733
   PubMed Web of Science ®Google Scholar
• Singh G, Singh AT, Abraham A, Bhat B, Mukherjee A, Verma R, Agarwal SK, Jha S, Mukherjee R, Burman AC. Protective effects of Terminalia arjuna against Doxorubicin-induced cardiotoxicity. J Ethnopharmacol 2008; 117: 123–129
   PubMed Web of Science ®Google Scholar
• Goormaghtigh E, Ruysschaert JM. Anthracycline glycoside-membraneinteractions. Biochim Biophys Acta 1984; 779: 271–288
   PubMed Web of Science ®Google Scholar
• Herman EH, Zhang J, Chadwick DP, Ferrans VJ. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 2000; 45: 329–334
   PubMed Web of Science ®Google Scholar